ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 216,29
-1,07%
Dow Jones
42 342,24
0,00%
DAX
19 728,68
-1,35%
Brent Oil
72,275
-0,15%
Bitcoin
95 023,87
-2,51%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) Actualités

BCRX

BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BCRX
DateHeureSourceTitreSymboleSociété
17/12/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/12/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/12/202422h15GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
18/11/202408h00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in IrelandNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/11/202413h00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/11/202423h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413h00GlobeNewswire Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
24/10/202414h00GlobeNewswire Inc.BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
21/10/202413h00GlobeNewswire Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4NASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/10/202413h00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/10/202413h00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/10/202413h00GlobeNewswire Inc.BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeNASDAQ:BCRXBioCryst Pharmaceuticals Inc
30/09/202413h00GlobeNewswire Inc.U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/09/202413h00GlobeNewswire Inc.BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/09/202418h09Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/09/202408h00GlobeNewswire Inc.BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/09/202413h00GlobeNewswire Inc.BioCryst Appoints Dr. Donald Fong Chief Medical OfficerNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/08/202422h38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/08/202413h00GlobeNewswire Inc.BioCryst Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/08/202411h46IH Market NewsU.S. Index Futures and Oil Prices Plunge on Recession ConcernsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/07/202413h00GlobeNewswire Inc.BioCryst to Report Second Quarter 2024 Financial Results on August 5NASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/06/202410h00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/05/202413h00GlobeNewswire Inc.BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/05/202413h00GlobeNewswire Inc.ORLADEYO® (berotralstat) Approved in MexicoNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/05/202413h00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/05/202413h00GlobeNewswire Inc.BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/04/202413h00GlobeNewswire Inc.BioCryst to Report First Quarter 2024 Financial Results on May 6NASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/04/202410h30GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
27/02/202423h05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:BCRX

Dernières Valeurs Consultées

EU
SGO
Cie de SaintGobain
COIN
DOGEUSD
Dogecoin
EU
ML
Michelin
EU
BEL20
Bel 20
EU
VIV
Vivendi
EU
BN
Danone
COIN
SOLUSD
Solana
COIN
AVAXUSD
Avalanche
COIN
XRPUSD
Ripple
EU
AF
Air FranceKLM
EU
EN
Bouygues
NASDAQ
MSFT
Microsoft
EU
GLE
Societe Generale
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés